I have done an in-depth analysis of the data from the PREMiSe clinical trial which tested the safety and efficacy of correcting CCSVI for MS. There can be no doubt that the University of Buffalo press release and video on this have no substance and are nothing more than unscientific, highly subjective, anti-CCSVI information concocted to discourage CCSVI treatment.

Notably the data from PREMiSe when analysed in an objective fashion support the value of CCSVI treatment for MS.

It is also Important to note that some of the researchers involved with PREMiSe are in a major conflict of interest in that they receive large sums of money from MS drug companies. Because CCSVI treatment has the potential to replace drug therapy in some cases, the compromised researchers and their drug company benefactors would potentially financially gain from a bogus claim that CCSVI treatment was of no value and might even be harmful.

The Quick Summary of my analysis is

The actual data from the PREMiSe Trial do not support the highly publicized claim that CCSVI correction by angioplasty is not of value for MS and may worsen disease activity. In sharp contrast, the data suggest that CCSVI correction may well be of substantial value for MS. The misleading claims made by University of Buffalo researchers are based on irrelevant data from the failed Phase 2 portion of the trial in which no one had their CCSVI corrected. The anti-CCSVI bias and baseless claims may be explained by the conflicts of interest.

The full evaluation can be accessed at

http://www.direct-ms.org/sites/default/files/Embry%20Premise%20Evaluation%20April%202013.pdf